The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement

Molecular Psychiatry

Volumn 14, Issue 4, 2009, Pages 448-461

  Engel, S R ^a   Creson, T K ^a   Hao, Y ^a   Shen, Y ^a   Maeng, S ^a   Nekrasova, T ^b   Landreth, G E ^b   Manji, H K ^a   Chen, G ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; ERK; Lithium; Mania; Neurotrophin; Valproate

Indexed keywords

AMPHETAMINE; LITHIUM CARBONATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; OLANZAPINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CONTROL; BIPOLAR DISORDER; BRAIN REGION; CAGE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; ENZYME SUBSTRATE; EXCITEMENT; HIPPOCAMPUS; HYPERACTIVITY; MALE; MAZE TEST; MOOD CHANGE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOANALYTIC THEORY; SIGNAL TRANSDUCTION; SWIMMING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LITHIUM CHLORIDE; LOCOMOTION; MAZE LEARNING; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 3; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; SWIMMING; VALPROIC ACID;

EID: 62849084624     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002135     Document Type: Article

References (74)

1. Kelleher III RJ, Govindarajan A, Tonegawa S. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 2004; 44: 59-73.
2. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004; 5: 173-183.
3. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 2004; 14: 311-317.
4. Chen G, Manji HK. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry 2006; 19: 313-323.
5. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-642.
6. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160.
7. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151.
8. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547.
9. Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD. Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn Mem 2001; 8: 11-19.
10. Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 2002; 34: 807-820.
11. Cestari V, Costanzi M, Castellano C, Rossi-Arnaud C. A role for ERK2 in reconsolidation of fear memories in mice. Neurobiol Learn Mem 2006; 86: 133-143.
12. Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press: New York, 1990.
13. Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351: 476-486.
14. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
15. Chen G, Creson T, Sharon E, Hao Y, Wang G. Neurotrophic actions of mood-stabilizers: a recent research discovery and its potential clinical applications. Curr Psychiatry Rev 2005; 1: 173-185.
16. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90.
17. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann NY Acad Sci 2005; 1053: 195-204.
18. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-31683.
19. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590-6599.
20. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J neurochem 2000; 75: 1729-1734.
21. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-7316.
22. Crawley JN. What's Wrong With My Mouse. Wiley-Liss: New York, 2000.
23. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-245.
24. Decker S, Grider G, Cobb M, Li XP, Huff MO, El-Mallakh RS et al. Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 455-462.
25. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-732.
26. Cox C, Harrison-Read PE, Steinberg H, Tomkiewicz M. Lithium attenuates drug-induced hyperactivity in rats. Nature 1971; 232: 336-338.
27. Wieland S, Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 1990; 101: 497-504.
28. Werme M, Messer C, Olson L, Gilden L, Thoren P, Nestler EJ et al. Delta FosB regulates wheel running. J Neurosci 2002; 22: 8133-8138.
29. Lett BT, Grant VL, Koh MT, Flynn G. Prior experience with wheel running produces cross-tolerance to the rewarding effect of morphine. Pharmacol Biochem Behav 2002; 72: 101-105.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. American Psychiatric Association: Washington DC, 2000.
31. Reeves G, Schweitzer J. Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother 2004; 5: 1313-1320.
32. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000; 157: 1108-1114.
33. Peet M, Peters S. Drug-induced mania. Drug Saf 1995; 12: 146-153.
34. Gainetdinov RR, Caron MG. An animal model of attention deficit hyperactivity disorder. Mol Med Today 2000; 6: 43-44.
35. Gould TD, O'Donnell K C, Picchini AM, Manji HK. Strain differences in lithium attenuation of D-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 2007; 32: 1321-1333.
36. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000; 2(Part 2): 261-268.
37. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283: 397-401.
38. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 2007; 37: 244-255.
39. Einat H, Manji HK, Belmaker RH. New approaches to modeling bipolar disorder. Psychopharmacol Bull 2003; 37: 47-63.
40. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006; 31: 2405-2414.
41. Sakamoto T, Mishina M, Niki H. Mutation of NMDA receptor subunit epsilon 1: effects on audiogenic-like seizures induced by electrical stimulation of the inferior colliculus in mice. Brain Res Mol Brain Res 2002; 102: 113-117.
42. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000; 25: 195-200.
43. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004; 29: 1050-1062.
44. Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten H, Cryan JF. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 2005; 16: 307-310.
45. Ferguson SM, Fasano S, Yang P, Brambilla R, Robinson TE. Knockout of ERK1 enhances cocaine-evoked immediate early gene expression and behavioral plasticity. Neuropsychopharmacology 2006; 31: 2660-2668.
46. Lucki I, O'Leary OF. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 2004; 65(Suppl 4): 11-24.
47. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005; 4: 775-790.
48. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol psychiatry 2002; 7: 1039-1053.
49. Weeber EJ, Sweatt JD. Molecular neurobiology of human cognition. Neuron 2002; 33: 845-848.
50. Avale ME, Falzone TL, Gelman DM, Low MJ, Grandy DK, Rubinstein M. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Mol psychiatry 2004; 9: 718-726.
51. Avale ME, Nemirovsky SI, Raisman-Vozari R, Rubinstein M. Elevated serotonin is involved in hyperactivity but not in the paradoxical effect of amphetamine in mice neonatally lesioned with 6-hydroxydopamine. J Neurosci Res 2004; 78: 289-296.
52. Abulaban FS, Dhariwal MA, al-Bekairi AM, Raza M. Antinociceptive activity of sodium valproate in mice after chronic treatment. Gen pharmacol 1997; 29: 463-467.
53. Li S, Murakami Y, Wang M, Maeda K, Matsumoto K. The effects of chronic valproate and diazepam in a mouse model of posttraumatic stress disorder. Pharmacol Biochem Behav 2006; 85: 324-331.
54. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 1997; 129: 79-84.
55. Duncan GE, Moy SS, Lieberman JA, Koller BH. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol Biochem Behav 2006; 85: 481-491.
56. Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002; 96: 45-66.
57. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158-1164.
58. Berridge MJ. The Albert Lasker medical awards. Inositol trisphosphate, calcium, lithium, and cell signaling. JAMA 1989; 262: 1834-1841.
59. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
60. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
61. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-390.
62. Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol psychiatry 2007; 61: 661-670.
63. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepress-antinduced behavioral effects. J Neurosci 2003; 23: 349-357.
64. Zorner B, Wolfer DP, Brandis D, Kretz O, Zacher C, Madani R et al. Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than 'depressive'. Biol psychiatry 2003; 54: 972-982.
65. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
66. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-3261.
67. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827-10832.
68. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-868.
69. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519-525.
70. Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, Barrot M et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol psychiatry 2003; 54: 994-1005.
71. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
72. Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 2002; 22: 10883-10890.
73. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-3268.
74. Conti AC, Kuo YC, Valentino RJ, Blendy JA. Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment. J Neurosci 2004; 24: 1967-1975.